IOM report suggests how to fix weaknesses in US paediatrics laws
This article was originally published in SRA
Executive Summary
A report by the Institute of Medicine has identified ways to strengthen the current US legislation for motivating or requiring pharmaceutical companies to conduct paediatric studies, including giving the Food and Drug Administration flexibility to impose sanctions for unreasonably delayed studies1.